Extended-release amphetamine (Dyanavel XR) is associated with reduced immediate-release supplementation in adults with ADHD, regardless of baseline patient variables: a retrospective cohort analysis of medical treatment records

Table 3 Magnitude of the change from baseline in psychometric assessments in patients with and without IR supplementation at 90 days^a

		Change from baseline
	n	Min	Max	Mean	SD	Cohen’s d^b
Patients with IR supplementation at 90 days
ASSET	23	-1.68	2.91	0.7570	1.11	0.68
PHQ-9	23	-10.00	18.00	0.8261	5.04	0.16
GAD-2	23	-6.00	1.00	− 0.3478	1.47	0.24
CGI-S	21	-2.00	1.00	0.0952	0.62	0.15
CGI-I	20	-1.00	1.00	− 0.0500	0.51	0.10
Patients without IR supplementation at 90 days
ASSET	385	-2.60	4.12	0.3858	0.98	0.39
PHQ-9	392	-14.00	15.00	1.4311	4.11	0.34
GAD-2	393	-6.00	5.00	0.2468	1.48	0.17
CGI-S	371	-2.00	3.00	0.1186	0.65	0.18
CGI-I	360	-3.00	4.00	0.2361	1.07	0.22

ASSET, ADHD Symptom and Side Effect Tracking; CGI-S, Clinical Global Impressions-Severity; CGI-I, Clinical Global Impressions-Improvement; ER, extended release; GAD-2, Generalized Anxiety Disorder 2-Item; PHQ-9, Patient Health Questionnaire-9
^a The visit falling closest to 90 days after ER stimulant was prescribed
^b Indicating the magnitude of the change from baseline (small: Cohen’s d = 0.2, medium: Cohen’s d = 0.5, large: Cohen’s d ≥ 0.8)

ISSN: 1471-244X